Cystic Fibrosis Lung Disease and Immunometabolism. Targeting the NLRP3 Inflammasome
- PMID: 31487198
- PMCID: PMC6884041
- DOI: 10.1164/rccm.201908-1558ED
Cystic Fibrosis Lung Disease and Immunometabolism. Targeting the NLRP3 Inflammasome
Figures

Comment on
-
Specific Inhibition of the NLRP3 Inflammasome as an Antiinflammatory Strategy in Cystic Fibrosis.Am J Respir Crit Care Med. 2019 Dec 1;200(11):1381-1391. doi: 10.1164/rccm.201905-1013OC. Am J Respir Crit Care Med. 2019. PMID: 31454256
References
-
- Stoltz DA, Meyerholz DK, Welsh MJ. Origins of cystic fibrosis lung disease. N Engl J Med. 2015;372:1574–1575. - PubMed
-
- Cantin AM, Bilodeau G, Ouellet C, Liao J, Hanrahan JW. Oxidant stress suppresses CFTR expression. Am J Physiol Cell Physiol. 2006;290:C262–C270. - PubMed
-
- Le Gars M, Descamps D, Roussel D, Saussereau E, Guillot L, Ruffin M, et al. Neutrophil elastase degrades cystic fibrosis transmembrane conductance regulator via calpains and disables channel function in vitro and in vivo. Am J Respir Crit Care Med. 2013;187:170–179. - PubMed
-
- Corriveau S, Sykes J, Stephenson AL. Cystic fibrosis survival: the changing epidemiology. Curr Opin Pulm Med. 2018;24:574–578. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical